This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Repligen Corporation, a bioprocessing company, focuses on the development, production, and commercialization of products used in the production of monoclonal antibodies, recombinant proteins, and vaccines.View RGEN
Repligen Corp - RGEN - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Repligen Corp as a
Hold with a ratings score of C+.
Report Snippet: We rate REPLIGEN CORP (RGEN) a HOLD. The primary factors that have impacted our rating are mixed – some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year.